Daraxonrasib Approved for Metastatic Pancreatic Cancer
Key Points FDA approved daraxonrasib (RASONQUE) on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma after at least one
Read MoreKey Points FDA approved daraxonrasib (RASONQUE) on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma after at least one
Read MoreNew Immune Map Reveals Key Insights for Pancreatic Cancer Treatment A newly constructed immune map has revealed distinct immune cell
Read More